Back

Digital seed amplification assay for TDP-43 aggregate quantification in CSF

Borberg, E.; Swank, Z. N.; Wickland Shearer, L.; Melkonian, A. V.; Rolando, J. C.; Walt, D. R.; Stern, A. M.

2025-10-15 neurology
10.1101/2025.10.14.25338017 medRxiv
Show abstract

INTRODUCTIONDementia is commonly caused by underlying pathologies driven by misfolded protein aggregates. Although dementia subtypes have distinct mechanisms, overlapping symptoms make diagnosis without biomarkers difficult. Misdiagnosis has previously hindered drug development by enrolling patients non-specifically in trials. METHODSWe developed a digital Seed amplification assay (dSAA) that isolates individual aggregates in nanoliter compartments, enabling precise quantification of TDP-43 seeds in cerebrospinal fluid (CSF). RESULTSTesting 40 CSF samples from patients with genetic and sporadic FTLD-TDP, as well as healthy controls, we found elevated seed concentrations in FTLD-TDP patients that correlated with disease severity, demonstrating the potential of dSAA as a sensitive diagnostic tool. DISCUSSIONThis study demonstrates a new quantitative, high-sensitivity digital assay for TDP-43 seeds in CSF. The platforms single-aggregate resolution and low LOD establish a technical foundation for developing a diagnostic and monitoring tool for FTLD-TDP and other TDP-43-related diseases.

Published in Alzheimer's & Dementia · not in our set (fewer than 10 published preprints to learn from) · training set

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.